A kind of chemotherapeutic immune combination medicine and preparation method thereof

A technology for chemoimmune and chemotherapeutic drugs, applied in drug combinations, pharmaceutical formulations, anti-tumor drugs, etc., can solve the problems of damage to normal organs, high toxicity and side effects of chemotherapy, and low clinical response rate, and achieves high dosage and high drug delivery. Many times, good slow release effect

Active Publication Date: 2021-11-09
SUZHOU INNOVATIVE BIOMATERIALS & PHARM CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, traditional chemotherapy drugs can also damage normal organs, and the commonly used chemotherapy mode in clinic is systemic administration, which is not very selective for the lesion, and the side effects of chemotherapy are very serious
[0003] Although tumor immunotherapy represented by immune checkpoint blockade has made encouraging achievements in recent years, this therapy still has important limitations, including low clinical response rate (about 20%), non-specific immune response side effects, etc.
In particular, the low clinical response rate of current clinical immune checkpoint blockade therapy means that most patients do not respond to this expensive therapy

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of chemotherapeutic immune combination medicine and preparation method thereof
  • A kind of chemotherapeutic immune combination medicine and preparation method thereof
  • A kind of chemotherapeutic immune combination medicine and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0135] Example 1: Preparation and use of sodium alginate (the first type of component) and imiquimod (the third type of component) hydrochloride composition freeze-dried powder injection

[0136] Step 1: Preparation of imiquimod (the third component) hydrochloride. Weigh 50-100 mg of imiquimod into a 50 ml glass mixing container, add 1 ml of 1M dilute hydrochloric acid therein, and add deionized water to dilute after the white powdery imiquimod is fully dissolved until it is colorless and transparent, so that The final concentration of imiquimod is 2.5-5 mg / ml. The solution was freeze-dried to obtain freeze-dried powder of imiquimod hydrochloride. The purpose of this step is to convert the water-insoluble imiquimod into the water-soluble hydrochloride form. Sufficient lyophilization time is required to ensure complete removal of hydrochloric acid residues.

[0137] Step 2: The following three methods can be used to prepare the freeze-dried powder injection of the hydrochlor...

Embodiment 2

[0151] Example 2: Sodium alginate (the first type of component) and CpG oligonucleotide (the third type of component) composition freeze-dried powder injection

[0152] Step 1: Preparation of sodium alginate and CpG oligonucleotide composition freeze-dried powder injection

[0153] Weighing 10-80 mg of sodium alginate and 0.1-5 mg of CpG oligonucleotides are dissolved in 1 ml of aqueous phase solution, fully shaken until the solution is clear and transparent, and then freeze-drying the solution to obtain a freeze-dried powder injection of the composition.

[0154] Figure 5 It is a scanning electron microscope picture of the freeze-dried powder injection of the composition after reconstitution into a gel. It can be seen from the figure that the composition still has good gelation ability after freeze-drying and reconstitution, and from the electron microscope pictures, it can be seen that there are many micron-scale pores after gelation, which is of great help to the sustaine...

Embodiment 3

[0163] Embodiment three: Sodium alginate (the first type of component) and doxorubicin hydrochloride (the second type of component) composition freeze-dried powder injection

[0164] Step 1: Preparation of freeze-dried powder injection of sodium alginate and doxorubicin hydrochloride composition:

[0165] Method 1: Weigh 20-80 mg of sodium alginate and 0.1-10 mg of doxorubicin hydrochloride and dissolve them in 1 ml of aqueous phase solution, stir with a stirring paddle at a speed of 50-300 rpm until the solution is clear and transparent, and then dissolve The solution is freeze-dried to obtain a freeze-dried powder injection of the composition.

[0166] Method 2: Dissolve 0.1-10 mg of doxorubicin hydrochloride in 1 ml of aqueous phase solution, stir with a stirring paddle at a speed of 50-300 rpm until the solution is clear and transparent, and then dissolve 10-80 mg of sodium alginate Into the aqueous phase solution, add the constantly stirring doxorubicin hydrochloride sol...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
Login to view more

Abstract

The invention discloses a chemotherapeutic-immune combination medicine, which is composed of a first mixture and a second mixture, the first mixture contains the immune adjuvant imiquimod R837, and the second mixture contains the chemotherapeutic drug Oxa capable of causing immunogenic death Liplatin, including poloxamer 188 and sodium alginate ALG; the first mixture is imiquimod emulsion obtained by mixing imiquimod R837 and poloxamer 188, and the imiquimod particles are 0.5-3 microns Particle size, the imiquimod emulsion is sterilized by high temperature and damp heat; the second mixture is sodium alginate ALG, oxaliplatin and water, stirred and mixed, and filtered and sterilized by a micron filter membrane to form a mixture. The present invention provides a novel anticancer pharmaceutical composition capable of producing synergistic anticancer effects, reducing side effects, reducing the probability of cancer metastasis, and reducing the probability of cancer recurrence. The growth of metastatic tumors and the probability of tumor recurrence, at the same time, the production process is relatively optimized, and the product stability is good.

Description

technical field [0001] The present invention relates to the field of drugs for treating tumors, in particular to a drug composition for combination therapy with chemotherapy and immunity, as well as a preparation method and application. Background technique [0002] Chemotherapy is one of the three main treatment methods for clinical treatment of tumors. Most cancer patients need to receive a certain degree of chemotherapy. For those tumors that have a tendency to metastasize or have metastasized, chemotherapy is the main treatment. However, traditional chemotherapy drugs can also damage normal organs, and the commonly used chemotherapy mode in clinic is systemic administration, which is not very selective for the lesion, and the side effects of chemotherapy are very serious. [0003] Although tumor immunotherapy represented by immune checkpoint blockade has made encouraging achievements in recent years, this therapy still has important limitations, including low clinical re...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K39/39A61K31/555A61K31/704A61K31/513A61K31/675A61K39/395A61K47/36A61K47/10A61P35/00A61P35/04
CPCA61K39/39A61K31/555A61K31/704A61K31/513A61K31/675A61K47/36A61K47/10A61P35/00A61K2039/55511A61K45/06A61K2300/00Y02A50/30
Inventor 刘庄许欢陶惠泉巢宇赵琪
Owner SUZHOU INNOVATIVE BIOMATERIALS & PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap